Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT06180460 Recruiting - Clinical trials for Metastatic Breast Cancer

CALM: Managing Distress in Malignant Brain Cancer

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM), compared to treatment as usual (TAU) in those with malignant brain cancer diagnoses.

NCT ID: NCT06165419 Recruiting - Clinical trials for Metastatic Breast Cancer

Definitive Radiation for High-Risk Spine Metastases

Start date: December 14, 2023
Phase: Phase 2
Study type: Interventional

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

NCT ID: NCT06161181 Recruiting - Clinical trials for Metastatic Breast Cancer

Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients

Start date: May 3, 2023
Phase: N/A
Study type: Interventional

Background: Emerging evidence indicates that patients with advanced cancer, such as those with MBC, often exhibit significant levels of nonadherence to oral anticancer treatments. Leveraging of the machine learning models in clinical practice enables the provision of personalized predictions on medication adherence for individual patients, thereby supporting adherence and facilitating targeted interventions. Objective: The current protocol aims to assess the efficacy of the DSS, a web-based solution named TREAT (TREatment Adherence SupporT), and a machine learning web application in promoting adherence to oral anticancer treatments within a sample of MBC patients. Methods and Design: This protocol is part of a project titled "Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients" (Tracking Number 65080791). A sample of 100 MBC patients is enrolled consecutively and admitted to the Division of Medical Senology of the European Institute of Oncology. 50 MBC patients receive the DSS for three months (experimental group), while 50 MBC patients not subjected to the intervention receive standard medical advice (control group). The protocol foresees three assessment time points: T1 (1-Month), T2 (2-Month), and T3 (3-Month). At each time point, participants fill out a set of self-reports evaluating adherence, clinical, psychological, and QoL variables. Conclusions: our results will inform about the effectiveness of the DSS and risk-predictive models in fostering adherence to oral anticancer treatments in MBC patients.

NCT ID: NCT06154590 Not yet recruiting - Chronic Pain Clinical Trials

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NASBP-B-09
Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX (tamoxifen citrate) did not demonstrate any efficacy benefit when compared to NOLVADEX (tamoxifen citrate) therapy given alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial. This study is now a combination therapy whereas the median duration of adjuvant treatment for safety evaluation is 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and NOLVADEX (tamoxifen citrate) 20 mg, respectively.

NCT ID: NCT06151249 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.

NCT ID: NCT06145399 Recruiting - Breast Cancer Clinical Trials

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Start date: October 24, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.

NCT ID: NCT06144346 Recruiting - Breast Cancer Clinical Trials

Metastases Directed Therapy for Oligometastatic Breast Cancer

Start date: September 20, 2023
Phase: N/A
Study type: Interventional

This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not

NCT ID: NCT06135714 Recruiting - Breast Cancer Clinical Trials

Metastasis-directed Therapy for Oligometastases of Breast Cancer

OLIGAMI
Start date: November 8, 2023
Phase: Phase 3
Study type: Interventional

OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group. After the first registration, all patients will be performed in a 12-week, subtype-specific, systemic therapy consisting of CDK4/6 inhibitors with hormonal therapy for luminal BC, docetaxel with trastuzumab and pertuzumab for HER2-positive BC, chemotherapy with immune checkpoint inhibitors for triple-negativeBC expressing PD-L1, and olaparib for cases harboring BRCA mutations. For other triple-negative BC, chemotherapy will be administered. If this 12-week systemic therapy does not cause any progression or complete response, patients proceed to second registration for randomization; arm A continues same systemic therapy alone, and arm B performs MDT followed by same systemic therapy. The MDT will involve either RT or surgery, and RT will involve mainly SBRT and partly conventional RT.

NCT ID: NCT06120283 Recruiting - Clinical trials for Non-small Cell Lung Cancer

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

NCT ID: NCT06110793 Recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Start date: December 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.